Understanding how CD56 affects human natural killer cells
Defining the functional role of CD56 on human natural killer cells
['FUNDING_R01'] · COLUMBIA UNIVERSITY HEALTH SCIENCES · NIH-10908665
This study is looking at a protein called CD56 on immune cells that help fight viruses and cancer, to see how it works with other parts of these cells and how changes to it might improve cancer treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | COLUMBIA UNIVERSITY HEALTH SCIENCES (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10908665 on ClinicalTrials.gov |
What this research studies
This research investigates the role of CD56, a protein found on human natural killer (NK) cells, which are essential for fighting viral infections and monitoring tumors. The study aims to explore how CD56 interacts with other components of NK cells and influences their function, particularly in the context of cancer immunotherapy. Researchers will examine how modifications to CD56 affect its behavior and how it connects to the cell's internal structure. By understanding these mechanisms, the research hopes to enhance the effectiveness of NK cell-based treatments for cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers that may benefit from enhanced NK cell activity.
Not a fit: Patients with conditions unrelated to NK cell function or those not diagnosed with cancer may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer immunotherapies that utilize natural killer cells more effectively.
How similar studies have performed: Previous research has shown promising results in understanding NK cell functions, but this specific focus on CD56 is relatively novel.
Where this research is happening
NEW YORK, UNITED STATES
- COLUMBIA UNIVERSITY HEALTH SCIENCES — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MACE, EMILY MARGARET — COLUMBIA UNIVERSITY HEALTH SCIENCES
- Study coordinator: MACE, EMILY MARGARET
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers